This medicine is authorised for use in the European Union.


Qinlock is a cancer medicine used to treat gastrointestinal stromal tumour (GIST), a cancer of the stomach and bowel, in adults with advanced disease who have already been treated with three or more medicines of the ‘kinase inhibitor’ class, including a medicine called imatinib.

GIST is rare, and Qinlock was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 12 October 2017.

Qinlock contains the active substance ripretinib.

This EPAR was last updated on 30/08/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Gastrointestinal Stromal Tumors
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.


This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Deciphera Pharmaceuticals (Netherlands) B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Atrium Building Floor 4th
Strawinskylaan 3051
1077 ZX Amsterdam
The Netherlands

Product information

21/06/2023 Qinlock - EMEA/H/C/005614 - IB/0012

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Assessment history

Related content

How useful was this page?

Add your rating